Trichomonas vaginalis (trichomonas) is of public health concern because of its association with HIV transmission, adverse birth outcomes and reproductive health. Trichomonas has been described as a neglected infection with varied perceptions of its importance despite associated outcomes. Remote and regional Aboriginal and Torres Strait Islander communities experience high rates of trichomonas along with chlamydia and gonorrhoea infections, where delays in the return of laboratory test results affect timely management. Trichomonas point-of-care (POC) testing was integrated into routine practice in 2018 alongside chlamydia/gonorrhoea POC testing at remote and regional Aboriginal and Torres Strait Islander primary care clinics participating in the Test Treat ANd GO (TTANGO2) research translation program (2016-2019). Trichomonas POC tests are performed with a separate cartridge from the combined chlamydia/gonorrhoea cartridge. The epidemiology of trichomonas is highly skewed towards women with a broader age range and longer duration of infection than bacterial STIs, potentially influencing health workers’ perceptions and uptake of POC testing. While there is broad acceptability of chlamydia/gonorrhoea POC testing, the acceptability of the additional use of trichomonas POC testing in remote settings is unknown.